Oncolytic virus cancer therapy - Pipeline Insight, 2022

DelveInsight’s, “Oncolytic virus cancer therapy – Pipeline Insight, 2022,” report provides comprehensive insights about 40+ companies and 80+ pipeline drugs in Oncolytic virus cancer therapy pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered
• Global coverage

Oncolytic virus cancer therapy Understanding
Oncolytic virus cancer therapy: Overview
Oncolytic virus (OV) cancer therapies are the virus based therapeutic strategies that infect and destroy cancer cells, and therefore act as an in situ cancer vaccine by releasing tumor-specific antigens. Viruses such as myxoma virus or reovirus have inherent selectivity to tumor cells, while being nonpathogenic to healthy human cells. On the other hand, other OVs, including adenovirus, herpes simplex virus type-1 (HSV-1), and vesicular stomatitis virus (VSV), have been genetically engineered to function as vectors to boost anti-tumor immune responses. The therapeutic efficacy of Oncolytic viruses depends on two main modes of action: First, Oncolytic viruses can inhibit protein synthesis of tumor cells and destroy infected tumor cells by self-replication. After viral infection, Oncolytic viruses continue self-replication until the cell bursts; Second, Oncolytic viruses can recruit and activate tumor-infiltrating immune cells by releasing a large amount of tumor antigens and secreting cytokines. Oncolytic virus cancer therapies can be used for diagnosis as well treatment of cancer. The anti-tumor efficacies of these OVs have been evaluated in many preclinical and clinical studies as monotherapy and combination therapy.

""Oncolytic virus cancer therapy - Pipeline Insight, 2022"" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Oncolytic virus cancer therapy pipeline landscape is provided which includes the disease overview and Oncolytic virus cancer therapy treatment guidelines. The assessment part of the report embraces, in depth Oncolytic virus cancer therapy commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Oncolytic virus cancer therapy collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights
• The companies and academics are working to assess challenges and seek opportunities that could influence Oncolytic virus cancer therapy R&D. The therapies under development are focused on novel approaches to treat/improve Oncolytic virus cancer therapy.

Oncolytic virus cancer therapy Emerging Drugs Chapters
This segment of the Oncolytic virus cancer therapy report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Oncolytic virus cancer therapy Emerging Drugs
• CG0070: CG Oncology
CG0070 is an investigational oncolytic immunotherapy based on a modified common cold adenovirus backbone that contains a cancer-specific promoter and a GM-CSF transgene. CG0070, first replicates inside the tumor’s cells causing tumor cell lysis and immunogenic cell death. Then, the rupture of the cancer cells can release tumor-derived antigens, along with GM-CSF, that can stimulate a systemic anti-tumor immune response that involves the body’s own white blood cells. CG0070 is in development for a variety of solid tumor types to be used alone or in combination with immune checkpoint modulators. The therapy is in clinical development for the treatment of Bladder cancer and preclinical studies for solid tumors. In advanced clinical studies, CG0070 has been shown to be a safe and efficacious agent in NMIBC following BCG failure.

• ONCOS-102: Targovax
ONCOS-102 is a genetically modified oncolytic adenovirus, which has been engineered to selectively infect cancer cells and activate the immune system to fight the cancer. ONCOS-102 is currently being tested in mesothelioma, melanoma and peritoneal malignancies and has shown promising clinical results both as monotherapy and in combination with chemotherapy, and a checkpoint inhibitor. In February 2021, Targovax announced that ONCOS-102 has received Fast-Track designation in malignant pleural mesothelioma from the US FDA.
Further product details are provided in the report……..

Oncolytic virus cancer therapy: Therapeutic Assessment
This segment of the report provides insights about the different Oncolytic virus cancer therapy drugs segregated based on following parameters that define the scope of the report, such as:
• Major Players in Oncolytic virus cancer therapy
There are approx. 40+ key companies which are developing the therapies for Oncolytic virus cancer therapy. The companies which have their Oncolytic virus cancer therapy drug candidates in the most advanced stage, i.e. Phase III include, CG Oncology.
• Phases
DelveInsight’s report covers around 40+ products under different phases of clinical development like
• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

• Route of Administration
Oncolytic virus cancer therapy pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
• Oral
• Parenteral
• Intravenous
• Subcutaneous
• Topical.
• Molecule Type

Products have been categorized under various Molecule types such as
• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy
• Product Type
Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Oncolytic virus cancer therapy: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Oncolytic virus cancer therapy therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Oncolytic virus cancer therapy drugs.

Oncolytic virus cancer therapy Report Insights
• Oncolytic virus cancer therapy Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Oncolytic virus cancer therapy Report Assessment
• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions
Current Treatment Scenario and Emerging Therapies:
• How many companies are developing Oncolytic virus cancer therapy drugs?
• How many Oncolytic virus cancer therapy drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Oncolytic virus cancer therapy?
• What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Oncolytic virus cancer therapy therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Oncolytic virus cancer therapy and their status?
• What are the key designations that have been granted to the emerging drugs?

Companies

• Affinia Therapeutics
• Lacerta Therapeutics
• Lokon Pharma AB
• Merck Sharp & Dohme Corp.
• Wuhan Binhui Biotechnology
• CG oncology
• BioVex Limited
• Oncolys BioPharma Inc.
• Replimmune
• Transgene
• Sorrento therapeutics
• ORCA therapeutics
• TILT Biotherapeutics
• Bioeclipse therapeutics
• Oncolys BioPharma
• Oncorus
• DNAtrix
• OncoMyx
• Vyriad
• VCN Biosciences
• Boehringer Ingelheim
• IconOVir
• Immugene
• AbbVie
• Turnstone Biologics